Remix Therapeutics

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi

Roche is to collaborate with Ascidian Therapeutics to discover and develop novel RNA exon editing therapeutics targeting neurological diseases, in a deal that could be worth up to $1.8bn. The Bosto

Like many other big pharma companies, Roche Holding AG spent 2023 looking for late-stage assets to meet their short-term needs ahead of a looming patent cliff. With several large deals now signed, t

In a sure sign that the annual J.P. Morgan Healthcare Conference in San Francisco will soon be under way, the waning days of December and the first week of January brought a deluge of new funding anno